NCT06413498

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Name: Clinical Trial NCT06413498
Creator: Kite, A Gilead Company
Keywords: Multiple Myeloma, Anitocabtagene Autoleucel, Phase 3, drug, clinical trial

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

Kite, A Gilead Company·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Multiple Myeloma
Drug/Device/Intervention: Anitocabtagene Autoleucel
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Kite, A Gilead Company
Funder: Gilead Sciences

Timeline & enrollment

Phase: Phase 3
Start date: Oct 01, 2024
End date: Jul 01, 2031
Enrollment: 450 participants

Primary outcome

Progression-Free Survival (PFS)

Summary

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug.  The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded independent review committee (IRC).

ICD-10 classifications

Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06413498
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06413498 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kite, A Gilead Company and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 450 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.